SIC
AXSM icon

Salem Investment Counselors’s Axsome Therapeutics AXSM Stock Holding History

Salem Investment Counselors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-500
Closed -$16K – 1066
2021
Q3 		$16K Buy
+500
New +$19.5K ﹤0.01% 683

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Salem Investment Counselors's AXSM Position: Q4 2021 in Review

Salem Investment Counselors sold out of Axsome Therapeutics (AXSM) in Q4 2021, closing a stake of 500 shares — an estimated $16K sold.

Salem Investment Counselors first reported a position in AXSM in Q3 2021 and held it in 1 quarter. The position peaked at $16K in Q3 2021. 167 funds tracked by Wall St. Rank hold AXSM as of Q4 2021.

  • Salem Investment Counselors reported no remaining Axsome Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Salem Investment Counselors sold 500 Axsome Therapeutics shares in Q4 2021, an estimated $16K.
  • Salem Investment Counselors first reported a position in Axsome Therapeutics in Q3 2021 and held it in 1 quarter.
  • Salem Investment Counselors's Axsome Therapeutics position peaked at $16K in Q3 2021.
  • 167 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2021.

Based on Salem Investment Counselors's 13F filing for Q4 2021, filed 15 Feb 2022.